Perspectives

How does this study impact clinical practice?

• The strengths of the study include its randomized, placebo-controlled design, high retention rate after randomization, and comprehensive assessments of body composition and cardiometabolic risk factors.
• Among the limitations, there was limited power to detect differences in secondary outcomes and limited representation of non-white participants.
• Exenatide XR compared to placebo was modestly effective at mitigating weight regain.
• The effects of exenatide XR on cardiometabolic risk factors was difficult to assess given normal baseline values.
• Further studies are needed to understand how other GLP1-RAs compare to exenatide XR and identify predictors of response to GLP1-RAs.